O
OrbiMed Portfolio holdings
AUM
$4.89B
1-Year Est. Return
87.75%
This Fund
S&P 500
1 Year Est. Return
+87.75%
AUM
$4.89B
AUM Growth
+$717M
(+17%)
Holding
126
Top Buys
| 1 | +$41.7M | |
| 2 | +$37.3M | |
| 3 | +$33.5M | |
| 4 |
HELP
Cybin Inc
HELP
|
+$24.7M |
| 5 |
Bruker
BRKR
|
+$23.5M |
Top Sells
| 1 | +$125M | |
| 2 | +$65.8M | |
| 3 | +$51.6M | |
| 4 |
Axsome Therapeutics
AXSM
|
+$38.9M |
| 5 |
SI-BONE Inc
SIBN
|
+$38M |
Sector Composition
| 1 | Healthcare | 99.56% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Edgewise Therapeutics
EWTX
$3.22B
| $385M | 7.88% |
15,518,492
|
|
||
2
Eli Lilly
LLY
$992B
| $324M | 6.62% |
301,200
|
|
||
3
Boston Scientific
BSX
$114B
| $231M | 4.72% |
2,419,300
-10,000
|
|
||
|
SVA
4
DELISTED
Sinovac Biotech, Ltd
SVA
| $184M | 3.78% |
2,718,735
|
|
||
5
Edwards Lifesciences
EW
$50.2B
| $157M | 3.22% |
1,842,900
+158,900
|
|
||
|
UPB
6
Upstream Bio Inc
UPB
$415M
| $155M | 3.16% |
5,693,589
|
|
||
7
Intuitive Surgical
ISRG
$179B
| $149M | 3.05% |
263,400
-23,800
|
|
||
|
SION
8
Sionna Therapeutics
SION
$1.63B
| $147M | 3% |
3,561,655
-143,304
|
|
||
|
MBX
9
MBX Biosciences
MBX
$1.46B
| $124M | 2.54% |
3,935,203
-67,684
|
|
||
10
argenx
ARGX
$47.5B
| $123M | 2.51% |
146,000
-26,300
|
|
||
11
Enliven Therapeutics
ELVN
$1.76B
| $123M | 2.51% |
7,959,538
|
|
||
12
Alnylam Pharmaceuticals
ALNY
$44.2B
| $115M | 2.35% |
288,800
-12,800
|
|
||
13
Stryker
SYK
$148B
| $114M | 2.34% |
325,000
-34,200
|
|
||
14
ARS Pharmaceuticals
SPRY
$917M
| $96.6M | 1.98% |
8,288,510
|
|
||
15
Terns Pharmaceuticals
TERN
$4.58B
| $87M | 1.78% |
2,153,300
-5,409,671
|
|
||
16
Disc Medicine
IRON
$2.51B
| $84.8M | 1.73% |
1,067,550
-347,470
|
|
||
|
CAI
17
Caris Life Sciences
CAI
$5.68B
| $84.1M | 1.72% |
3,116,011
+81,153
|
|
||
18
Natera
NTRA
$29B
| $83.8M | 1.71% |
365,800
-63,500
|
|
||
19
Compass Therapeutics
CMPX
$1B
| $81.7M | 1.67% |
15,219,994
|
|
||
20
Structure Therapeutics
GPCR
$4.45B
| $80.8M | 1.65% |
1,161,803
+22,503
|
|
||
21
Danaher
DHR
$149B
| $68.6M | 1.4% |
299,800
+36,700
|
|
||
22
CG Oncology
CGON
$4.86B
| $63M | 1.29% |
1,516,550
-210,300
|
|
||
23
Apellis Pharmaceuticals
APLS
$2.68B
| $61M | 1.25% |
2,429,868
+106,500
|
|
||
24
ArriVent BioPharma
AVBP
$948M
| $60.9M | 1.25% |
3,027,328
|
|
||
25
Cigna
CI
$76.4B
| $56.4M | 1.15% |
205,000
+42,200
|
|